The relationship between SLC16A1-AS1 expression level and the clinicopathologic characteristics of BC patients analyzed by the chi-square test showed that the SLC16A1-AS1 expression was statistically significantly related to tumor size, TNM stage, lymph node metastasis, and WIF1 expression but not related to age, gender, and tumor differentiation of patients (Supplementary Table 2). This evidence concerns the gene SLC16A1 and breast cancer.